DGRO vs XBI
iShares Core Dividend Growth ETF vs SPDR S&P Biotech ETF
- • DGRO has the lower expense ratio at 0.08% vs 0.35% for XBI.
- • DGRO pays a higher dividend yield (1.95%).
Side-by-side metrics
| Metric | DGRO | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.08% | 0.35% |
Dividend yield Trailing 12-month yield. | 1.95% | 0.36% |
AUM Assets under management — bigger funds are typically more liquid. | $41.23B | $10.73B |
YTD return | 11.68% | 33.79% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.68 | 1.10 |
P/E ratio | 23.53 | — |
Last price | $77.00 | $164.01 |
Inception | — | — |
Issuer | iShares | State Street |
DGRO top holdings
| JNJ | Johnson & Johnson | 3.12% |
| ABBV | AbbVie Inc | 3.05% |
| JPM | JPMorgan Chase & Co | 3.03% |
| AAPL | Apple Inc | 2.76% |
| MSFT | Microsoft Corp | 2.67% |
| XOM | Exxon Mobil Corp | 2.60% |
| AVGO | Broadcom Inc | 2.55% |
| HD | The Home Depot Inc | 2.33% |
| PG | Procter & Gamble Co | 2.26% |
| PM | Philip Morris International Inc | 2.08% |
XBI top holdings
| APGE | Apogee Therapeutics Inc | 1.49% |
| MRNA | Moderna Inc | 1.41% |
| TWST | Twist Bioscience Corp | 1.41% |
| ORKA | Oruka Therapeutics Inc | 1.38% |
| KYMR | Kymera Therapeutics Inc Ordinary Shares | 1.36% |
| VKTX | Viking Therapeutics Inc | 1.30% |
| PRAX | Praxis Precision Medicines Inc Ordinary Shares | 1.29% |
| ERAS | Erasca Inc | 1.27% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 1.20% |
| RYTM | Rhythm Pharmaceuticals Inc | 1.20% |
About DGRO
DGRO (iShares Core Dividend Growth ETF) is US stocks with sustained dividend growth. Managed by iShares, the fund carries $41.2B in assets under management, an expense ratio of 0.08%, a dividend yield of 1.95%. Its largest holding is Johnson & Johnson (JNJ), which represents 3.1% of the portfolio. Consumer Cyclical is the fund's largest sector exposure at 6.5%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $10.7B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.36%. Its largest holding is Apogee Therapeutics Inc (APGE), which represents 1.5% of the portfolio. Financial Services is the fund's largest sector exposure at 0.5%.